- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04698330
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Latent autoimmune diabetes in adults (LADA) is a hybrid form of diabetes, characterized by autoimmune destruction of pancreatic β-cells as well as insulin resistance and is triggered by environmental factors in the context of genetic susceptibility. Meanwhile,blood glucose management is the cornerstone of diabetes care and poor glycemic control will cause a series of diabetes complications. This study will focus on improving the quality of life of LADA patients and blood glucose management as the starting point to explore the improvement effects of combined drugs on the development of diabetes.
Inulin is a common prebiotic that has been shown to improve glycemic control, alter the gut microbiota and suppress inflammation. Berberine(BBR), a small alkaloid isolated from medicinal plants, has been reported to have many therapeutic effects, including anti-bacteria, anti-diabetes, and lipid-lowering. Besides, studies revealed that BBR exerts antidiabetic effects by modulating gut microbiota. In a multicentre, randomized, double-blinded, placebo-controlled 12-week clinical trial conducted in 409 drug-naive T2D patients, Wang et al. confirmed the hypoglycaemic effect of BBR in Chinese participants and demonstrated the BBR-induced changes in the human gut microbiome in comparison with the placebo. Moreover, Ho et al. conducted a randomized, placebo-controlled trial in 38 children with type 1 diabetes using placebo or prebiotic oligofructose-enriched inulin for 12 weeks, and found that oral supplement of the prebiotic could improve glycemic status and β cell function. So we speculate that BBR and inulin combination can also improve glycemic control in the patients with LADA.
This study is a prospective, randomized, double-blind, placebo-controlled trial. The study comprises once screening, the 1-month run-in period, the 3-month treatment period and the 9-month follow-up period. After obtaining the informed consent from the patient who is willing to participate the 3-month treatment will enter to the 1-month run-in period. According to the inclusion/exclusion criteria, the eligible patients will be randomized to the 3-month treatment period. Patients will be randomized into four groups : BBR-alone, inulin+BBR, inulin-alone, or placebo. The primary outcome is to assess the change in glycated hemoglobin levels. Dynamic blood glucose parameters, β-cell function and gut microbiota, as well as adverse events and quality of life will be monitored.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Yang Xiao, MD/PhD
- Phone Number: 86-731-85292154
- Email: xiaoyang29@csu.edu.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
-
Contact:
- Yang Xiao, MD/PhD
- Phone Number: 86-0731-85292154
- Email: xiaoyang29@csu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diabetes diagnosed according to the report of WHO in 1999;
- Meet the Chinese Diabetes Society diagnostic criteria (2012) for LADA: (1)glutamic acid decarboxylase antibody (GADA) positive; (2) age at diagnosis ≧ 18 years old; (3) independent on insulin for more than 6 months after diagnosis;
- Aged between 18 and 70 years old;
- 7.0%≤HbA1c ≤10.0%;
- BMI ≥ 18.5 kg/m2, and no more than 37.5 kg/m2;
- Written informed consent from the patient or family representative.
Exclusion Criteria:
- Severe liver dysfunction (ALT and AST greater than 3 times the upper limit of detection);
- eGFR < 50ml/(min • 1.73 m2);
- Evidence of acute or chronic infection affecting glycemic control within 4 weeks prior to the first visit;
- History of any malignancy;
- Pregnancy, breastfeeding, or planned pregnancy during the study period;
- Secondary diabetes;
- Presence of acute complications (ketoacidosis, lactic acidosis or hyperosmolar coma);
- Severe organic heart disease, including but not limited to congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, etc., New York Heart Association (NYHA) heart function classification ≥Grade III;
- Chronic use of systemic glucocorticoids or other immunosuppressive agents for over 3 months,or use of antibiotic medications or other interventions that could affect the gastrointestinal tract for 2 months before the screening and during the whole study period.
- History of hemolytic anemia or glucose-6-phosphate dehydrogenase deficiency.
- Allergic to berberine or any components in the combinations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
LADA patients are assigned to receive berberine and inulin for 3-month.
|
0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
|
Experimental: Group B
LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.
|
0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
|
Experimental: Group C
LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.
|
0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
|
Placebo Comparator: Group D
LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.
|
0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: 1 year after start of trial
|
The primary outcome measure is the change in mean HbA1c level, reflecting the blood glucose management status of the patients.
|
1 year after start of trial
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in C-peptide
Time Frame: 1 year after start of trial
|
C-peptide are measured before and after a mixed meal tolerance test.
|
1 year after start of trial
|
Incidence of acute and chronic diabetes complications
Time Frame: 1 year after start of trial
|
In this study, the chronic diabetes complications recorded mainly include diabetic macrovascular disease, diabetic nephropathy, diabetic retinopathy and peripheral neuropathy.
|
1 year after start of trial
|
Change in gut permeability
Time Frame: 1 year after start of trial
|
Gut permeability is measured by amount of mannitol and lactulose in urine.
|
1 year after start of trial
|
Change in gut microbiota composition
Time Frame: 1 year after start of trial
|
The changes of gut microbiota are mainly detected by multi omics technology.
|
1 year after start of trial
|
Assessment of quality of life
Time Frame: 1 year after start of trial
|
Quality of life will be assessed by the Chinese version of the Audit of Diabetes Dependent Quality of Life (ADDQoL-19).
|
1 year after start of trial
|
Gastrointestinal side effects and other drug-related side effects
Time Frame: 1 year after start of trial
|
The gastrointestinal side effects need to be self-reported by the patient, such as nausea, vomiting, diarrhea, constipation, flatulence, etc.
|
1 year after start of trial
|
Hypoglycemic events
Time Frame: 1 year after start of trial
|
Hypoglycemia events are divided into mild hypoglycemia and severe hypoglycemia.
|
1 year after start of trial
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yang Xiao, MD/PhD, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China
Publications and helpful links
General Publications
- Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, Ma J, Gu X, Xue Y, Huang S, Yang J, Chen L, Chen G, Qu S, Liang J, Qin L, Huang Q, Peng Y, Li Q, Wang X, Kong P, Hou G, Gao M, Shi Z, Li X, Qiu Y, Zou Y, Yang H, Wang J, Xu G, Lai S, Li J, Ning G, Wang W. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020 Oct 6;11(1):5015. doi: 10.1038/s41467-020-18414-8.
- Ho J, Nicolucci AC, Virtanen H, Schick A, Meddings J, Reimer RA, Huang C. Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4427-4440. doi: 10.1210/jc.2019-00481.
- Zhang R, Xiao Y, Yan J, Yang W, Wu X, Mei Z, Zhou Z. Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: Protocol for a Randomized Controlled Trial. Front Endocrinol (Lausanne). 2022 Jun 15;13:876657. doi: 10.3389/fendo.2022.876657. eCollection 2022.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020LADACP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Berberine
-
Tianjin Anding HospitalCompletedSchizophrenia | Metabolic Syndrome | FemaleChina
-
University of FloridaFlorida High Tech Corridor Council; Designs for Health, Inc.Completed
-
EuroPharma, Inc.Scientific Center of Drug and Medical Technologies Expertise of the Ministry... and other collaboratorsNot yet recruiting
-
Xijing Hospital of Digestive DiseasesCompleted
-
Factors Group of Nutritional Companies Inc.CompletedPharmacokineticsCanada
-
National Cancer Institute (NCI)CompletedUlcerative ColitisUnited States, China
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina
-
Tang YidaChinese Society of CardiologyNot yet recruitingMetabolic SyndromeChina
-
Ayub Teaching HospitalCompletedPolycystic Ovary SyndromePakistan
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedDiabetes Mellitus | Chronic Kidney DiseaseChina